Entity map — Cyana Therapeutics

Cyana Therapeutics Organization

Precision immuno-oncology company developing drugs to treat solid tumors.

Canonical: https://cyanatx.com/

• Cyana Therapeutics is a precision immuno-oncology company developing drugs to treat solid tumors. Its lead compound, CY-3132, is a small molecule inhibitor of an enzyme called ENPP1, which is upregulated on the surface of many tumor cells.

  Source: Cyana Therapeutics | Precision Immuno-Oncology · definition · publisher: Cyana Therapeutics

• Cyana's pipeline: CY-3132 (subcutaneous injection), an ENPP1 inhibitor for solid tumors in oncology, is at the IND-enabling stage with Phase 1 planned for 2026. CY-3292 (oral), an ENPP1 inhibitor for rare disease applications, is in lead optimization.

  Source: Cyana Therapeutics | Precision Immuno-Oncology · fact · publisher: Cyana Therapeutics

Shoshana Shendelman Person

Co-Founder and CEO of Cyana Therapeutics; scientist and entrepreneur, founder of several biotech companies.

Same as: https://drshendelman.com/about/shoshana-shendelman/ · https://shoshanashendelman.com/ · https://cyanatx.com/about/dr-shoshana-shendelman · https://www.linkedin.com/in/shoshana-shendelman-phd-8756926/ · https://x.com/drshendelman · https://www.youtube.com/@DrShendelman · https://www.facebook.com/shoshanashendelman · https://www.forbes.com/profile/shoshana-shendelman/ · https://scholar.google.com/citations?user=CaGnZOUAAAAJ&hl=en · https://www.realclearmarkets.com/authors/shoshana_shendelman/ · https://www.foxnews.com/person/s/shoshana-shendelman · https://orcid.org/0000-0002-7016-5295 · https://www.researchgate.net/profile/Shoshana-Shendelman · https://www.bloomberg.com/profile/person/21035645 · https://www.crunchbase.com/person/shoshana-shendelman-shendelman · https://secretary.columbia.edu/directory/shoshana-shendelman · https://people.equilar.com/bio/person/shoshana-shendelman-columbia-university/27810884 · https://wbcollaborative.org/women_leaders_ceo/shoshana-shendelman-ph-d/ · https://www.iawfoundation.org/community/shoshana-shendelman/profile/

• Shoshana Shendelman, PhD is the Co-Founder and CEO of Cyana Therapeutics. She is a scientist and entrepreneur, founder of several biotech companies, and a pioneer in developing drugs for rare and underserved diseases. She previously founded and led a public pharmaceutical company through IPO and multiple financing rounds, with drugs advancing to phase 3 development for rare disease and heart failure indications.

  Source: Shoshana Shendelman, PhD — Co-Founder & CEO, Cyana Therapeutics · definition · publisher: Cyana Therapeutics

• Dr. Shendelman holds a PhD from Columbia University Vagelos College of Physicians and Surgeons, plus MA and MSc degrees from Columbia; her doctoral research focused on molecular mechanisms of Parkinson's Disease. She earned a BA in biochemistry from Brandeis University, holds numerous patents, and has published in journals including Orphanet Journal of Rare Diseases and PLoS Biology.

  Source: Shoshana Shendelman, PhD — Co-Founder & CEO, Cyana Therapeutics · credential · publisher: Cyana Therapeutics

Jessica Dennison Person

Chief Operating Officer of Cyana Therapeutics; translational scientist and biotech entrepreneur.

• Dr. Jessica Dennison is a translational scientist and emerging biotech entrepreneur. She serves as Chief Operating Officer of Cyana Therapeutics, where she manages cross-functional teams and external partners, leads business development, and supports fundraising.

  Source: Jessica Dennison, PhD — COO, Cyana Therapeutics · definition · publisher: Cyana Therapeutics